Recognizing and treating a new entity on the quality-of-life front: Small intestinal bacterial overgrowth

Community Oncology

Volumn 4, Issue 10, 2007, Pages 625-629

  Jahraus, Christopher D ^a   Brandt, Sandra ^b   Bettenhausen, Doug ^c  

^a Gadsden Regional Cancer Center   (United States)

^b The University of Alabama at Birmingham   (United States)

^c Salix a Division of Valeant Pharmaceuticals North America LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAXIMIN;

ARTICLE; BACTERIAL GROWTH; BREATH ANALYSIS; CANCER THERAPY; DIARRHEA; GASTROINTESTINAL DISEASE; HUMAN; INTESTINE FLORA; PUBLICATION; QUALITY OF LIFE;

EID: 35548966305     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70044-4     Document Type: Article

References (28)

1. American Cancer Society. Cancer Facts and Figures 2006. Atlanta: American Cancer Society; 2006.
2. Crane CH, Evans DB, Wolff RA, et al. The pancreas. In: Cox JD, Ang KK, eds. Radiation Oncology, Rationale-Techniques-Results. 8th ed. St. Louis, MO: Mosby; 2003:465-480.
3. Carratù R, Secondulfo M, de Magistris L, et al. Assessment of small intestinal damage in patients treated with pelvic radiotherapy. Oncol Rep 1998;5:635-639.
4. Summers RW, Flatt AJ, Prihoda MJ, Mitros FA. Effect of irradiation on morphology and motility of canine small intestine. Dig Dis Sci 1987;32:1402-1410.
5. Summers RW, Glenn CE, Flatt AJ, Elahmady A. Does irradiation produce irreversible changes in canine jejunal myoelectric activity? Dig Dis Sci 1992;37:716-722.
6. Otterson MF, Sarna SK, Moulder JE. Effects of fractionated doses of ionizing radiation on small intestinal motor activity. Gastroenterology 1988;95:1249-1257.
7. Pia de la Maza M, Gotteland M, Ramirez C, et al. Acute nutritional and intestinal changes after pelvic radiation. J Am Coll Nutr 2001;20:637-642.
8. Duncan M, Grant G. Oral and intestinal mucositis - causes and possible treatments. Aliment Pharmacol Ther 2003;18:853-874.
9. Swan RW. Stagnant loop syndrome resulting from small-bowel irradiation injury and intestinal by-pass. Gynecol Oncol 1974;2:441-445.
10. Weiss RG, Stryker JA. 14-C lactose breath tests during pelvic radiotherapy: the effect of the amount of small bowel irradiated. Radiology 1982;142:507-510.
11. Pimentel M, Kong Y, Park S. Breath testing to evaluate lactose intolerance in irritable bowel syndrome correlates with lactulose testing and may not reflect true lactose malabsorption. Am J Gastroenterol 2003;98:2700-2704.
12. Mettler L, Romeyke A, Brieler G. Effects of para- and post-irradiation abnormal bacteria flora and intestinal irradiation reaction through Bacterium bifidus substitution therapy. Strahlentherapie 1973;145:588-599.
13. Salminen E, Elomaa I, Minkkinen J, Vapaatalo H, Salminen S. Preservation of intestinal integrity during radiotherapy using live Lactobacillus acidophilus cultures. Clin Radiol 1988;39:435-437.
14. Ghoshal UC, Ghoshal U, Das K, Misra A. Utility of hydrogen breath tests in diagnosis of small intestinal bacterial overgrowth in malabsorption syndrome and its relationship with oro-cecal transit time. Indian J Gastroenterol 2006;25:6-10.
15. Urita Y, Ishihara S, Akimoto T, et al. Seventy-five gram glucose tolerance test to assess carbohydrate malabsorption and small bowel bacterial overgrowth. World J Gastroenterol 2006;12:3092-3095.
16. Lauritano EC, Gabrielli M, Lupascu A, et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005; 22:31-35.
17. Banks MR, Farthing MJ. Fluid and electrolyte transport in the small intestine. Curr Opin Gastroenterol 2002;18:176-181.
18. Nucera G, Gabrielli M, Lupascu A, et al. Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005;21:1391-1395.
19. Lupascu A, Gabrielli M, Lauritano EC, et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther 2005;22:1157-1160.
20. Pimentel M, Mayer AG, Park S, Chow EJ, Hasan A, Kong Y. Methane production during lactulose breath test is associated with gastrointestinal disease presentation. Dig Dis Sci 2003; 48:86-92.
21. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006;101:326-333.
22. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006;145:557-563.
23. Pedretti G, Calzetti C, Missale G, Fiaccadori F. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Ital J Gastroenterol 1991;23:175-178.
24. Festi D, Vestito A, Mazzella G, Roda E, Colecchia A. Management of hepatic encephalopathy: focus on antibiotic therapy. Digestion 2006;73(suppl 1):94-101.
25. Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005;51(suppl 1):36-66.
26. Baker DE. Rifaximin: a nonabsorbed oral antibiotic. Rev Gastroenterol Disord 2005;5:19-30.
27. Leevy CB, Phillips JA. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci 2007;52:737-741.
28. ABOUT THE AUTHORS Affiliations: Dr. Jahraus is an attending physician at the Gadsden Regional Cancer Center, Gadsden, AL; Ms. Brandt is a nurse in the Department of Radiation Oncology, University of Alabama-Birmingham, AL; and Dr. Bettenhausen is the Vice President of Medical Affairs and Product Safety, Salix Pharmaceuticals, Inc., Morrisville, NC. Conflicts of interest: Dr. Jahraus has served on a speakers' bureau and has received research funding from Salix Pharmaceuticals, Inc. Ms. Brandt has nothing to disclose. Dr. Bettenhausen is an employee of Salix Pharmaceuticals, Inc.